Achieve Life Sciences (ACHV)
(Delayed Data from NSDQ)
$4.58 USD
+0.04 (0.77%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.56 -0.02 (-0.33%) 6:16 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ACHV 4.58 +0.04(0.77%)
Will ACHV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACHV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ACHV
Jones starts Achieve Life Sciences at buy, cites market opportunity
Achieve Life Sciences: A Strong Buy for Tobacco Cessation Market Penetration
Achieve Life Sciences initiated with bullish view at JonesResearch, here's why
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
Analysts Offer Insights on Healthcare Companies: Forian (FORA), Achieve Life Sciences (ACHV) and P3 Health Partners (PIII)